Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial.

Abstract excerpt

Treatment recommendations for patients with hepatitis C virus (HCV) genotype (GT) 3b infection and cirrhosis remain unclear. This multicentre randomized controlled trial evaluated the efficacy of 12-week treatment with sofosbuvir/velpatasvir plus ribavirin (arm A) versus sofosbuvir/velpatasvir/voxilaprevir (arm B) in direct-acting antiviral (DAA)-naïve patients with HCV GT3b with compensated cirrhosis. Patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aminoisobutyric Acids
• Share to Benzopyrans